Member Info for Cloudy390

No you are not, I’m extremely bullish on this. Dr Weiner is also, listen to what says, this could be the turning point. He has always been excited about Foralumab so I expect news, but listen to what he says as last time he said ‘ if nothing else it works’.

Why a couple of years ,Bristol Meyers Squibb bought a hiv drug before it was even test for $5billion. With this potential and safety record I would have thought this would be a good buy especially as big pharma’s patents are expiring and all being quite ring fenced with patents .What a portfolio to buy

My bet is on , sold Accustem.

Laugh out loud. :-)

I’m no expert, but have read into the listing requirements which include ADR’s, and requirement is min $4 and /or bid price of between $2/$3, which is a firm general requirement for listing. So a min $2 bid price is what I understand it to be.
Anybody clarify further??

Enlighten me how they will get around the minimum share ADR price of $2 as a stipulation of Nasdaq listing, they would have to make an ADR a lot more than 2 shares or if they leave it 2 shares to one adr it will have to be a dollar per actual UK share that we will get.
Maybe GC will enlighten us in the next fortnight.
All seems a mystery to me.

I thought the minimum price a listing on Nasdaq is $2 so that would mean $1 a share ,about 75p.

Don’t like Tils, averous comes into play.No matter as it all depends on results. Sooooooon.

Novimmue took it to phase 2 with adverse events and BMS both sold the license to us and we (Tils)
Repurposed it in tablets and nasal/ nebuliser in minute doses to give a positive outcome.
Surely this has got to be bigger than the wheel , so to speak.
And they sold its companion ,the il6 up and coming candidate for a song , as far as I can see.
Come on You Tils!!
And blow me we have Accustem , a bit of a conundrum, but still there, for the holders who got shares.
What’s not to like!
And milciclib is available to the market most in need.
Bingo. Full house.

Float?
Answers on a post card.

I think about the UK-CTAP scheme ,the more I think this will be the game changer we need.
Phase 2 drug, exemplary safety record, easy administering, take home, effective in COVID and could prevent long COVID. Absolute no brainier, and the trial won’t be a long duration , could be used in public by Christmas, and as stated we have stock manufacted and waiting to be used.
And no interest in the shares LOL. Water , horse springs to mind.

A month of dosing for SPMS patient and now this new appointment, all bodes well methinks.

I looked on the other Blog and it showed a sell of that amount and then another at exactly the same time but put in the ? Column (unknown) but did not show on the totals, so all a bit confusing.

Way ahead now. unbelievable, come on you LSE.

Excellent news, don’t want to spread himself to thin, prioritise on Tils.

Brings to mind The grant Howard Weiner got last year to investigate the use of foralumab in Alzheimer’s. Some news on that must be forthcoming shorty as well I hope.

I can post link Denny, or do you want to see if Sangi has and can??? Lol

Exactly Bluebelly!
Possibly just getting StemprintER certified , buyer happy, Bobs your uncle!!

I see your point Bluebelly but surely the science so far is amazing, the market is there, there’s nothing stopping them progressing this like CE mark etc. And they don’t have to inform us of any progress. All seems very strange to me, that’s why I say buyout at fair value maybe on the cards. Saves a lot of fafing about listing etc.

Are still open then, come on you Tils , the suspense is killing me.
It’s got to be good surely with all this time to get it right.